← All Signals

🏥 FDA: Radnostix — Class III

healthcareneutralSource: FDA
70%Confidence
0Views
FDASource
2026-04-10Date

Summary

Radnostix's Class III recall for failed capsule specifications in a Sodium Iodide I-131 kit indicates minor quality issues unlikely to cause severe harm, but still points to manufacturing inconsistencies. This could lead to temporary supply constraints for nuclear medicine diagnostics, though the impact is limited due to the niche market.

Actionable: Monitor Radnostix for corrective actions but no immediate investment change is needed given the low-severity recall.

AI Confidence: 70%

Data Points

firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now